tiprankstipranks
Trending News
More News >
Atossa Therapeutics (ATOS)
NASDAQ:ATOS
Advertisement

Atossa Therapeutics (ATOS) Stock Statistics & Valuation Metrics

Compare
2,394 Followers

Total Valuation

Atossa Therapeutics has a market cap or net worth of $100.15M. The enterprise value is $49.24M.
Market Cap$100.15M
Enterprise Value$49.24M

Share Statistics

Atossa Therapeutics has 129,171,420 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding129,171,420
Owned by Insiders3.41%
Owned by Institutions0.71%

Financial Efficiency

Atossa Therapeutics’s return on equity (ROE) is -0.36 and return on invested capital (ROIC) is -38.64%.
Return on Equity (ROE)-0.36
Return on Assets (ROA)-0.33
Return on Invested Capital (ROIC)-38.64%
Return on Capital Employed (ROCE)-0.39
Revenue Per Employee0.00
Profits Per Employee-1.70M
Employee Count15
Asset Turnover0.00
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of Atossa Therapeutics is ―. Atossa Therapeutics’s PEG ratio is ―.
PE Ratio
PS Ratio
PB Ratio
Price to Fair Value1.66
Price to FCF
Price to Operating Cash Flow-4.06
PEG Ratio

Income Statement

In the last 12 months, Atossa Therapeutics had revenue of 0.00 and earned -25.50M in profits. Earnings per share was -0.20.
Revenue0.00
Gross Profit-17.00K
Operating Income-27.62M
Pretax Income-25.50M
Net Income-25.50M
EBITDA-25.49M
Earnings Per Share (EPS)-0.20

Cash Flow

In the last 12 months, operating cash flow was -25.02M and capital expenditures -19.00K, giving a free cash flow of -25.04M billion.
Operating Cash Flow-25.02M
Free Cash Flow-25.04M
Free Cash Flow per Share-0.19

Dividends & Yields

Atossa Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.92
52-Week Price Change-45.26%
50-Day Moving Average0.83
200-Day Moving Average0.88
Relative Strength Index (RSI)41.94
Average Volume (3m)1.08M

Important Dates

Atossa Therapeutics upcoming earnings date is Nov 17, 2025, TBA (Confirmed).
Last Earnings DateAug 12, 2025
Next Earnings DateNov 17, 2025
Ex-Dividend Date

Financial Position

Atossa Therapeutics as a current ratio of 14.99, with Debt / Equity ratio of 0.00%
Current Ratio14.99
Quick Ratio14.99
Debt to Market Cap0.00
Net Debt to EBITDA2.79
Interest Coverage Ratio0.00

Taxes

In the past 12 months, Atossa Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00

Enterprise Valuation

Atossa Therapeutics EV to EBITDA ratio is -1.87, with an EV/FCF ratio of -2.27.
EV to Sales0.00
EV to EBITDA-1.87
EV to Free Cash Flow-2.27
EV to Operating Cash Flow-2.27

Balance Sheet

Atossa Therapeutics has $57.86M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$57.86M billion.
Cash & Marketable Securities$57.86M
Total Debt$0.00
Net Cash-$57.86M
Net Cash Per Share-$0.45
Tangible Book Value Per Share$0.57

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%

Analyst Forecast

The average price target for Atossa Therapeutics is $5.63, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$5.63
Price Target Upside650.67% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast
EPS Growth Forecast-8.91%

Scores

Smart Score7
AI Score36
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis